What are the indications, contraindications, and adverse effects of glycopyrrolate?

Glycopyrrolate: Indications, Contraindications, and Adverse Effects

Indications

Glycopyrrolate is indicated for reduction of secretions and minimization of vagal responses in perioperative settings, management of excessive secretions in palliative care, and as an adjunct to anesthesia. 1, 2

Perioperative Use

• Preanesthetic medication: 0.004 mg/kg intramuscularly given 30-60 minutes before anesthesia induction to reduce secretions and minimize vagal response 3, 1, 2, 4
• Intraoperative use: Administered intravenously to counteract drug-induced or vagal reflexes and associated arrhythmias (e.g., bradycardia) 4
• Adjunct to ketamine anesthesia: Attenuates increased upper airway secretions that can cause severe dyspnea or sense of "suffocation" 1, 2
• Reversal of neuromuscular blockade: Used in combination with neostigmine for reversal of non-depolarizing neuromuscular blockade 5

Secretion Management

• Palliative care: 0.2-0.4 mg IV or subcutaneously every 4 hours as needed for excessive secretions in end-of-life care 1, 2
• Chronic drooling (sialorrhea): FDA-approved oral solution for children ages 3-16 years with neurologic disorders, initiated at 0.02 mg/kg per dose orally three times daily (maximum 3 mg per dose) 6, 7
• Bronchoscopy: Reduces bronchial secretions and attenuates vagal overactivity when administered before the procedure 1

Other Indications

• Hyperhidrosis: Topical formulations (2% glycopyrrolate or glycopyrronium cloth 2.4%) for excessive sweating, particularly facial and palmar hyperhidrosis 8, 9
• COPD: Inhaled glycopyrrolate as a long-acting muscarinic antagonist for maintenance treatment 10, 11
• Ménière's disease: Limited course for symptomatic management of acute vertigo attacks 3

Contraindications

The FDA label explicitly contraindicates glycopyrrolate in patients with known hypersensitivity and multiple conditions involving obstruction or severe cardiovascular instability. 4

Absolute Contraindications

• Known hypersensitivity to glycopyrrolate or any inactive ingredients 4
• Narrow-angle glaucoma: Can precipitate acute angle-closure events 1, 4
• Obstructive uropathy (e.g., bladder neck obstruction due to prostatic hypertrophy) 4
• Obstructive gastrointestinal disease (achalasia, pyloroduodenal stenosis) 4
• Paralytic ileus or intestinal atony in elderly or debilitated patients 4
• Unstable cardiovascular status in acute hemorrhage 4
• Severe ulcerative colitis or toxic megacolon complicating ulcerative colitis 4
• Myasthenia gravis 4

Special Population Warnings

• Neonates and infants: Contains benzyl alcohol, which has been associated with "gasping syndrome" (CNS depression, metabolic acidosis, gasping respirations) particularly in premature and low-birth-weight infants at doses >99 mg/kg/day 4
• Pediatric patients with Down's syndrome, spastic paralysis, or brain damage: May experience increased response to anticholinergics and heightened risk of side effects 4

Adverse Effects

Glycopyrrolate produces anticholinergic side effects that are extensions of its pharmacologic actions, but has significantly lower CNS penetration than atropine or scopolamine due to its quaternary ammonium structure. 4, 12

Common Adverse Effects (Peripheral Anticholinergic)

• Xerostomia (dry mouth): 9-41% in pediatric studies 4, 6
• Urinary hesitancy and retention: Inhibitory effect on bladder contraction and increased bladder hypotonia 4, 5
• Blurred vision and photophobia: Due to mydriasis (pupil dilation) 4
• Constipation: 9-39% in pediatric studies 4, 6
• Decreased sweating 4
• Tachycardia and palpitations 4

Less Common but Significant Adverse Effects

• Behavioral changes: 18-36% in pediatric patients, including paradoxical hyperexcitability with large doses 4, 6
• Mental confusion and/or excitement: Especially in elderly persons 4
• Nausea, vomiting, headache, nervousness, drowsiness, weakness, dizziness, insomnia 4
• Suppression of lactation, impotence 4

Serious Adverse Events (Post-Marketing Reports)

• Cardiac arrhythmias: Including bradycardia, ventricular tachycardia, ventricular fibrillation, and cardiac arrest 4
• Heart block and QTc interval prolongation: Particularly when combined with anticholinesterase agents 4
• Malignant hyperthermia 4
• Hypertension or hypotension 4
• Seizures and respiratory arrest 4
• Severe allergic reactions: Including anaphylactic/anaphylactoid reactions, hypersensitivity, urticaria, pruritus 4

Injection Site Reactions

• Pruritus, edema, erythema, and pain at injection sites 4

Comparative Safety Profile

Glycopyrrolate demonstrates a more favorable safety profile than other anticholinergics because it minimally crosses the blood-brain barrier, resulting in significantly lower risk of delirium, sedation, and confusion compared to scopolamine or atropine. 1, 2, 13, 4, 12 This quaternary amine structure limits CNS-related side effects while maintaining peripheral anticholinergic efficacy 4, 12. Glycopyrrolate is also associated with lower risk of tachycardia and pro-arrhythmic effects compared to atropine 1.

Critical Clinical Considerations

• Discontinuation rates: Approximately 20% of children with sialorrhea experience adverse effects severe enough to require discontinuation, even at low doses 7
• Dose-dependent effects: Adverse effects occur more frequently at higher doses 6
• Systemic absorption: Topical formulations can cause systemic anticholinergic effects including unilateral mydriasis (from inadvertent eye contact) and systemic absorption-related events similar to those seen with other routes 9
• No effect on serum sodium: Glycopyrrolate does not influence renal tubular sodium reabsorption or sodium homeostasis, and routine sodium monitoring is not required 1